// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Quality Improvement Project to improve use of Very Brief Advice to inpatient smokers in an acute respiratory ward

Chuen Ryan Khaw - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Relationship between markers of systemic inflammation and microstructural brain damage in COPD

Mohani-Preet Kaur Bajaj - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Systemic inflammation

Fibrinogen (IV)

Trends in smoking initiation in Australia over 70 years

Gulser Caliskan - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

National advisory services for multidrug-resistant tuberculosis (MDRTB) in Europe: an ERS-TBnet survey

Graham H. Bothamley - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

Bedaquiline

EBUS-TBNA in a paediatric population in London

Harriet Owles - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

N/A

Drug resistance and HIV rates are high in Eastern European patients with Tuberculosis in a South East London Hospital

Sharenja Ratnakumar - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

N/A

Extrapulmonary tuberculosis in patients with chronic kidney disease receiving renal replacement therapy

Emma Johnson - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Chronic kidney disease

N/A

Regional study on the management and coutcomes of Tuberculous Uveitis

Sayed Alderazi - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Uveitis

N/A

A Case Series of Pericardial TB in a large European Centre

Anand Sundaralingam - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Outcomes of new entrant TB screening in Bolton, UK

Gideon Katzenberg - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Interferon Gamma

The meaning of a high monocyte to lymphocyte ratio in tuberculosis

Tom Buttle - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

N/A

Do higher quantitative interferon gamma release assay or tuberculin skin test results help to predict incident tuberculosis? Data from the UK PREDICT study

Rishi Gupta - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

Interferon Gamma

Long-term incidence of tuberculosis among migrants according to migrant status: a cohort study

Kristina Langholz Kristensen - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

Mibefradil

Impact of the introduction of a paediatric ‘virtual TB clinic’

Louise Turnbull - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Posttransplant tuberculosis in Europe – a TBnet study

Berit Lange - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

N/A

Hypophosphatasia in adults at a specialist centre in the UK: the spectrum of musculoskeletal disease

Jalpa Kotecha - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hypophosphatasia

N/A

Is vitamin D testing essential in elderly patients with a hip fracture?

Serena N Mehta - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Ergocalciferol

The OA thumb therapy trial: a three arm multi-centre randomised controlled trial of the clinical effectiveness and efficacy of splints for symptomatic thumb base OA

Jo Adams - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Clinical and cost-effectiveness of ultrasound-guided intra-articular corticosteroid and local anaesthetic injection for hip OA: a randomised controlled trial (HIT)

Zoe Paskins - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Triamcinolone acetonide

How does radiographic knee OA impact musculoskeletal aging in midlife? Findings from the Hertfordshire Cohort study

Nicholas R Fuggle - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Osteoarthritis 2

N/A

Copyright © 2026. QuantiNova All rights reserved